Risa Labs has closed an USD 11.1 million Series A funding round to expand its footprint across cancer care delivery in the United States. The financing was co-led by Cencora Ventures and Optum Ventures, with participation from Oncology Ventures, Z21 Ventures and John Simon, co-founder of General Catalyst, through his Ventureforgood investment entity.

The fresh capital will support the rapid deployment of Risa’s AI platform across cancer clinics, health systems, specialty pharmacies and infusion networks, addressing long-standing administrative bottlenecks that delay patient access to treatment. By automating complex processes such as benefits verification and prior authorisation, it aims to transform manual, error-prone workflows into predictable and scalable operations across the oncology care continuum.

The company’s AI operating system integrates directly with Electronic Medical Records (EMRs), payer platforms, and benefits systems, enabling AI agents to read, reason and act across multiple environments. These agents prepare and submit authorisations, track payer responses and adapt in real time to changes in rules, forms, or interfaces—eliminating the need for constant reprogramming. The platform is specifically designed to manage the complexity of cancer care, including multi-drug regimens, disease-specific requirements, and varied payer policies.

Healthcare teams manage these workflows through Risa’s Boss Console, a centralised command and control interface that allows institutions to customise routing, documentation standards and practice-specific rules. Every AI action is fully traceable and audit-ready, providing transparency, compliance assurance and operational visibility for clinical and administrative leaders.

Looking ahead, RISA plans to deepen its focus on oncology by expanding AI-driven workflows across the full cancer care continuum, with specialty pharmacy operations identified as the next area of growth.